Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom

Summary

Skyhawk Therapeutics expanded its global pivotal FALCON-HD trial for SKY-0515 to the United States, Canada, and the United Kingdom, with over 175 patients now enrolled across more than ten countries and twenty sites. The drug has completed Phase 1/2 enrollment and demonstrated general tolerability with twelve months of patient data available.